CVS HEALTH Corp: Form 10-Q for the period ended Jun 30, 2021
Filed with the SEC on Aug 4, 2021 and accepted by EDGAR at Aug 4, 2021, 06:36 ET.
Management's discussion and analysis
As filed, 80,637 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Overview of Business
CVS Health Corporation (“CVS Health”), together with its subsidiaries (collectively, the “Company,” “we,” “our” or “us”), is a diversified health services company united around a common purpose of helping people on their path to better health. In an increasingly connected and digital world, we are meeting people wherever they are and changing health care to meet their needs. The Company has more than 9,900 retail locations, approximately 1,100 walk-in medical clinics, a leading pharmacy benefits manager with approximately 108 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year and expanding specialty pharmacy services. The Company also serves an estimated 34 million people through traditional, voluntary and consumer-directed health insurance products and related services, including expanding Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan (“PDP”). The Company believes its innovative health care model increases access to quality care, delivers better health outcomes and lowers overall health care costs.
The Company has four reportable segments: Health Care Benefits, Pharmacy Services, Retail/LTC and Corporate/Other, which are described below.
Overview of the Health Care Benefits Segment
The Health Care Benefits segment is one of the nation’s leading diversified health care benefits providers. The Health Care Benefits segment has the information and resources to help members, in consultation with their health care professionals, make more informed decisions about their health care. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPs, Medicaid health care management services, and health information technology products and services. The Health Care Benefits segment also provided workers’ compensation administrative services through its Coventry Health Care Workers’ Compensation business (“Workers’ Compensation business”) prior to the sale of this business on July 31, 2020. The Health Care Benefits segment’s customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers (“providers”), governmental units, government-sponsored plans, labor groups and expatriates. The Company refers to insurance products (where it assumes all or a majority of the risk for medical and dental care costs) as “Insured” and administrative services contract products (where the plan sponsor assumes all or a majority of the risk for medical and dental care costs) as “ASC.”
Overview of the Pharmacy Services Segment
The Pharmacy Services segment provides a full range of pharmacy benefit management (“PBM”) solutions, including plan design offerings and administration, formulary management, retail pharmacy network management services, mail order pharmacy, specialty pharmacy and infusion services, clinical services, disease management services, medical spend management and pharmacy and/or other administrative services for providers and Covered Entities. The Pharmacy Services segment’s clients are primarily employers, insurance companies, unions, government employee groups, health plans, PDPs, Medicaid managed care plans, plans offered on public health insurance exchanges and private health insurance exchanges, other sponsors of health benefit plans throughout the United States and Covered Entities. The Pharmacy Services segment operates retail specialty pharmacy stores, specialty mail order pharmacies, mail order dispensing pharmacies, compounding pharmacies and branches for infusion and enteral nutrition services.
Overview of the Retail/LTC Segment
The Retail/LTC segment sells prescription drugs and a wide assortment of health and wellness products and general merchandise, provides health care services through its MinuteClinic® walk-in medical clinics, provides medical diagnostic testing, administers vaccinations for illnesses such as influenza, coronavirus disease 2019 (“COVID-19”) and shingles and conducts long-term care pharmacy (“LTC”) operations, which distribute prescription drugs and provide related pharmacy consulting and other ancillary services to long-term care facilities and other care settings. As of June 30, 2021, the Retail/LTC segment operated more than 9,900 retail locations, approximately 1,100 MinuteClinic locations as well as online retail pharmacy websites, LTC pharmacies and onsite pharmacies.
Overview of the Corporate/Other Segment
The Company presents the remainder of its financial results in the Corporate/Other segment, which primarily consists of:
- Management and administrative expenses to support the Company’s overall operations, which include certain aspects of executive management and the corporate relations, legal, compliance, human resources, information technology and finance departments, expenses associated with the Company’s investments in its transformation and enterprise modernization programs and acquisition-related integration costs; and
- Products for which the Company no longer solicits or accepts new customers such as large case pensions and long-term care insurance products.
Overview of Current Trends
We also face trends and uncertainties specific to our reportable segments, certain of which are summarized below and also discussed in the review of our segment results. For the remainder of the year, the Company believes you should consider the following important information:
- The COVID-19 pandemic continues to impact the economies of the U.S. and other countries around the world. We believe COVID-19’s impact on our businesses, operating results, cash flows and/or financial condition primarily will be driven by the geographies impacted and the severity and duration of the pandemic, as well as the pandemic’s impact on the U.S. and global economies, consumer behavior and health care utilization patterns. In addition, as described in the “Government Regulation” section of the 2020 Form 10-K, federal, state and local governmental policies and initiatives designed to reduce the transmission of COVID-19 may not effectively combat the severity and/or duration of the COVID-19 pandemic, and have resulted in a myriad of impacts on our businesses. Those primary drivers are beyond our knowledge and control. As a result, the impact COVID-19 will have on our businesses, operating results, cash flows and/or financial condition is uncertain, but the impact could be adverse and material. Specific COVID-19 related impacts on the Company during the three and six months ended June 30, 2021 and 2020 are further described below.
- The Health Care Benefits segment is expected to experience lower Medicare risk adjustment revenue and modestly elevated medical costs for the remainder of the year, with non-COVID-19 related utilization returning towards baseline levels and continued COVID-19 related costs, largely related to treatment, testing and the administration of the vaccine. The Company also expects to incur higher operating expenses during the fourth quarter related to investments to support future growth and readiness for the start of the 2022 plan year.
- The Pharmacy Services segment is expected to continue to benefit from our ability to drive improvements in purchasing economics and growth in specialty pharmacy, albeit at a slower pace than experienced in the first half of the year, partially offset by continued price compression. We expect year-over-year growth to moderate in the remainder of the year due to operating results in the second half of 2020 reflecting the benefit of the launch of our group purchasing organization entity and specialty generic launches. The Company also expects to incur higher operating expenses during the fourth quarter related to investments to enhance operations, digital and clinical trials capabilities and readiness for the start of the 2022 plan year.
- The Retail/LTC segment is expected to continue to benefit from increased prescription volume and improved generic drug purchasing, partially offset by continued pharmacy reimbursement pressure. While COVID-19 diagnostic testing and vaccinations are expected to continue for the remainder of 2021, we expect vaccinations to slow in the second half of the year. The extent of COVID-19 vaccinations and diagnostic testing will be dependent upon various factors including vaccine hesitancy, the emergence of new variants and the availability and administration of pediatric and booster vaccinations.
- The Company is expected to continue to benefit from its cost savings initiatives, including ongoing digitalization and technology improvements, a reduction in non-retail real estate associated with workforce management changes and initiatives to increase productivity and operational efficiency. The Company also expects incremental investments in wages, including an increase in the minimum wage for store, warehouse and call center colleagues in support of its initiatives to retain and attract talent for its community health destinations.
Operating Results
The following discussion explains the material changes in the Company’s operating results for the three and six months ended June 30, 2021 and 2020, and the significant developments affecting the Company’s financial condition since December 31, 2020. We strongly recommend that you read our audited consolidated financial statements and notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations, which are included in the 2020 Form 10-K.
Summary of Consolidated Financial Results
In millions
| Revenues: | Three Months Ended June 30, 2021 | 2020 | Six Months Ended June 30, 2021 | 2020 | Change Three Months Ended June 30, 2021 vs 2020 $% | Six Months Ended June 30, 2021 vs 2020 $% | ||
|---|---|---|---|---|---|---|---|---|
| Products | $50,525 | $46,355 | $97,912 | $93,358 | $4,170 | 9.0% | $4,554 | 4.9% |
| Premiums | 18,983 | 16,927 | 37,943 | 34,567 | 2,056 | 12.1% | 3,376 | 9.8% |
| Services | 2,819 | 1,875 | 5,272 | 3,825 | 944 | 50.3% | 1,447 | 37.8% |
| Net investment income | 289 | 184 | 586 | 346 | 105 | 57.1% | 240 | 69.4% |
| Total revenues | 72,616 | 65,341 | 141,713 | 132,096 | 7,275 | 11.1% | 9,617 | 7.3% |
| Operating costs: | ||||||||
| Cost of products sold | 43,520 | 40,242 | 84,414 | 80,589 | 3,278 | 8.1% | 3,825 | 4.7% |
| Benefit costs | 15,901 | 11,751 | 31,605 | 26,138 | 4,150 | 35.3% | 5,467 | 20.9% |
| Operating expenses | 8,869 | 8,668 | 17,791 | 17,231 | 201 | 2.3% | 560 | 3.2% |
| Total operating costs | 68,290 | 60,661 | 133,810 | 123,958 | 7,629 | 12.6% | 9,852 | 7.9% |
| Operating income | 4,326 | 4,680 | 7,903 | 8,138 | (354) | (7.6)% | (235) | (2.9)% |
| Interest expense | 636 | 765 | 1,293 | 1,498 | (129) | (16.9)% | (205) | (13.7)% |
| Other income | (45) | (45) | (95) | (99) | — | —% | 4 | 4.0% |
| Income before income tax provision | 3,735 | 3,960 | 6,705 | 6,739 | (225) | (5.7)% | (34) | (0.5)% |
| Income tax provision | 944 | 974 | 1,690 | 1,741 | (30) | (3.1)% | (51) | (2.9)% |
| Net income | 2,791 | 2,986 | 5,015 | 4,998 | (195) | (6.5)% | 17 | 0.3% |
| Net income attributable to noncontrolling interests | (8) | (11) | (9) | (16) | 3 | 27.3% | 7 | 43.8% |
| Net income attributable to CVS Health | $2,783 | $2,975 | $5,006 | $4,982 | $(192) | (6.5)% | $24 | 0.5% |
Commentary - Three Months Ended June 30, 2021 vs. 2020
Revenues
- Total revenues increased $7.3 billion, or 11.1%, in the three months ended June 30, 2021 compared to the prior year driven by growth across all segments.
- Please see “Segment Analysis” later in this report for additional information about the revenues of the Company’s segments.
Operating expenses
- Operating expenses increased $201 million, or 2.3%, in the three months ended June 30, 2021 compared to the prior year. The increase in operating expenses was primarily due to incremental costs associated with growth in the business, including costs associated with COVID-19 vaccinations and diagnostic testing in the Retail/LTC segment. The increase was partially offset by the repeal of the HIF for 2021, the favorable impact of company-wide cost savings initiatives in 2021 and a $137 million gain from an anti-trust legal settlement, of which $125 million was included in the Retail/LTC segment and $12 million was included in the Pharmacy Services segment in the three months ended June 30, 2021.
- Operating expenses as a percentage of total revenues were 12.2% in the three months ended June 30, 2021, a decrease of 110 basis points compared to the prior year. The decrease in operating expenses as a percentage of total revenues was primarily due to the increases in total revenues described above.
- Please see “Segment Analysis” later in this report for additional information about the operating expenses of the Company’s segments.
Operating income
- Operating income decreased $354 million, or 7.6%, in the three months ended June 30, 2021 compared to the prior year primarily due to the return of more normalized utilization levels in the Health Care Benefits segment following a significant decrease in utilization during the three months ended June 30, 2020 due to the COVID-19 pandemic. The decrease in operating income in the three months ended June 30, 2021 was partially offset by increased prescription and front store volume, COVID-19 vaccinations and diagnostic testing in the Retail/LTC segment as well as improved purchasing economics and increased pharmacy claims volume in the Pharmacy Services segment during the three months ended June 30, 2021.
- Please see “Segment Analysis” later in this report for additional information about the operating results of the Company’s segments.
Interest expense
- Interest expense decreased $129 million, or 16.9%, in the three months ended June 30, 2021 compared to the prior year due to lower debt in the three months ended June 30, 2021. See “Liquidity and Capital Resources” later in this report for additional information.
Income tax provision
- The Company’s effective income tax rate was 25.3% for the three months ended June 30, 2021 compared to 24.6% for the three months ended June 30, 2020. The increase in the effective income tax rate in the three months ended June 30, 2021 was primarily due to the absence of the favorable impact associated with the resolution of several state and local income tax matters in the three months ended June 30, 2020, partially offset by the repeal of the non-deductible HIF for 2021.
Commentary - Six Months Ended June 30, 2021 vs. 2020
Revenues
- Total revenues increased $9.6 billion, or 7.3%, in the six months ended June 30, 2021 compared to the prior year driven by growth across all segments.
- Please see “Segment Analysis” later in this report for additional information about the revenues of the Company’s segments.
Operating expenses
- Operating expenses increased $560 million, or 3.2%, in the six months ended June 30, 2021 compared to the prior year. The increase in operating expenses was primarily due to incremental costs associated with growth in the business, including costs associated with COVID-19 vaccinations and diagnostic testing in the Retail/LTC segment. The increase was partially offset by the repeal of the HIF for 2021 and the favorable impact of company-wide cost savings initiatives in 2021.
- Operating expenses as a percentage of total revenues were 12.6% in the six months ended June 30, 2021, a decrease of 40 basis points compared to the prior year. The decrease in operating expenses as a percentage of total revenues was primarily due to the increases in total revenues described above.
- Please see “Segment Analysis” later in this report for additional information about the operating expenses of the Company’s segments.
Operating income
- Operating income decreased $235 million, or 2.9%, in the six months ended June 30, 2021 compared to the prior year. The decrease in operating income was primarily driven by the deferral of elective procedures and other discretionary utilization in response to the COVID-19 pandemic during the six months ended June 30, 2020 in the Health Care Benefits segment. The decrease was partially offset by improved purchasing economics in the Pharmacy Services segment and COVID-19 vaccinations and diagnostic testing in the Retail/LTC segment in the six months ended June 30, 2021.
- Please see “Segment Analysis” later in this report for additional information about the operating results of the Company’s segments.
Interest expense
- Interest expense decreased $205 million, or 13.7%, in the six months ended June 30, 2021 compared to the prior year due to lower debt in the six months ended June 30, 2021. See “Liquidity and Capital Resources” later in this report for additional information.
Income tax provision
- The Company’s effective income tax rate was 25.2% for the six months ended June 30, 2021 compared to 25.8% for the six months ended June 30, 2020. The decrease in the effective income tax rate in the six months ended June 30, 2021 was primarily due to the repeal of the non-deductible HIF for 2021, partially offset by the absence of the favorable impact associated with the resolution of several state and local income tax matters in the six months ended June 30, 2020.
Segment Analysis
The following discussion of segment operating results is presented based on the Company’s reportable segments in accordance with the accounting guidance for segment reporting and is consistent with the segment disclosure in Note 9 ‘‘Segment Reporting’’ to the unaudited condensed consolidated financial statements.
The Company has three operating segments, Health Care Benefits, Pharmacy Services and Retail/LTC, as well as a Corporate/Other segment. The Company’s segments maintain separate financial information, and the Company’s chief operating decision maker (the “CODM”) evaluates the segments’ operating results on a regular basis in deciding how to allocate resources among the segments and in assessing segment performance. The CODM evaluates the performance of the Company’s segments based on adjusted operating income, which is defined as operating income (GAAP measure) excluding the impact of amortization of intangible assets and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance. See the reconciliations of operating income (GAAP measure) to adjusted operating income below for further context regarding the items excluded from operating income in determining adjusted operating income. The Company uses adjusted operating income as its principal measure of segment performance as it enhances the Company’s ability to compare past financial performance with current performance and analyze underlying business performance and trends. Non-GAAP financial measures the Company discloses, such as consolidated adjusted operating income, should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP.
The following is a reconciliation of financial measures of the Company’s segments to the consolidated totals:
In millions
| Three Months Ended June 30, 2021 | Health Care Benefits | Pharmacy Services (1) | Retail/ LTC | Corporate/ Other | Intersegment Eliminations (2) | Consolidated Totals |
|---|---|---|---|---|---|---|
| Total revenues | $20,525 | $38,314 | $24,728 | $182 | $(11,133) | $72,616 |
| Adjusted operating income (loss) | 1,614 | 1,755 | 2,049 | (369) | (162) | 4,887 |
| June 30, 2020 | ||||||
| Total revenues | 18,468 | 34,889 | 21,662 | 86 | (9,764) | 65,341 |
| Adjusted operating income (loss) | 3,464 | 1,327 | 1,057 | (343) | (177) | 5,328 |
| Six Months Ended | ||||||
| June 30, 2021 | ||||||
| Total revenues | $41,008 | $74,635 | $48,002 | $317 | $(22,249) | $141,713 |
| Adjusted operating income (loss) | 3,396 | 3,262 | 3,443 | (672) | (337) | 9,092 |
| June 30, 2020 | ||||||
| Total revenues | 37,666 | 69,872 | 44,411 | 176 | (20,029) | 132,096 |
| Adjusted operating income (loss) | 4,955 | 2,508 | 2,959 | (628) | (353) | 9,441 |
(1) Total revenues of the Pharmacy Services segment include approximately $2.8 billion and $2.6 billion of retail co-payments for the three months ended June 30, 2021 and 2020, respectively, and $6.2 billion and $6.0 billion of retail co-payments for the six months ended June 30, 2021 and 2020, respectively.
(2) Intersegment revenue eliminations relate to intersegment revenue generating activities that occur between the Health Care Benefits segment, the Pharmacy Services segment, and/or the Retail/LTC segment. Intersegment adjusted operating income eliminations occur when members of Pharmacy Services Segment clients (“PSS members”) enrolled in Maintenance Choice® elect to pick up maintenance prescriptions at one of the Company’s retail pharmacies instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail/LTC segments record the adjusted operating income on a stand-alone basis.
The following are reconciliations of consolidated operating income (GAAP measure) to consolidated adjusted operating income, as well as reconciliations of segment GAAP operating income to segment adjusted operating income:
In millions
| Three Months Ended June 30, 2021 Health Care Benefits | Pharmacy Services | Retail/ LTC | Corporate/ Other | Intersegment Eliminations | Consolidated Totals | |
|---|---|---|---|---|---|---|
| Operating income (loss) (GAAP measure) | $1,273 | $1,705 | $1,919 | $(409) | $(162) | $4,326 |
| Amortization of intangible assets (1) | 402 | 50 | 130 | — | — | 582 |
| Acquisition-related integration costs (2) | — | — | — | 40 | — | 40 |
| Acquisition purchase price adjustment outside of measurement period (3) | (61) | — | — | — | — | (61) |
| Adjusted operating income (loss) | $1,614 | $1,755 | $2,049 | $(369) | $(162) | $4,887 |
In millions
| Three Months Ended June 30, 2020 Health Care Benefits | Pharmacy Services | Retail/ LTC | Corporate/ Other | Intersegment Eliminations | Consolidated Totals | |
|---|---|---|---|---|---|---|
| Operating income (loss) (GAAP measure) | $3,066 | $1,271 | $933 | $(413) | $(177) | $4,680 |
| Amortization of intangible assets (1) | 398 | 56 | 124 | — | — | 578 |
| Acquisition-related integration costs (2) | — | — | — | 70 | — | 70 |
| Adjusted operating income (loss) | $3,464 | $1,327 | $1,057 | $(343) | $(177) | $5,328 |
In millions
| Six Months Ended June 30, 2021 Health Care Benefits | Pharmacy Services | Retail/ LTC | Corporate/ Other | Intersegment Eliminations | Consolidated Totals | |
|---|---|---|---|---|---|---|
| Operating income (loss) (GAAP measure) | $2,653 | $3,157 | $3,184 | $(754) | $(337) | $7,903 |
| Amortization of intangible assets (1) | 804 | 105 | 259 | 1 | — | 1,169 |
| Acquisition-related integration costs (2) | — | — | — | 81 | — | 81 |
| Acquisition purchase price adjustment outside of measurement period (3) | (61) | — | — | — | — | (61) |
| Adjusted operating income (loss) | $3,396 | $3,262 | $3,443 | $(672) | $(337) | $9,092 |
In millions
| Six Months Ended June 30, 2020 Health Care Benefits | Pharmacy Services | Retail/ LTC | Corporate/ Other | Intersegment Eliminations | Consolidated Totals | |
|---|---|---|---|---|---|---|
| Operating income (loss) (GAAP measure) | $4,161 | $2,385 | $2,713 | $(768) | $(353) | $8,138 |
| Amortization of intangible assets (1) | 794 | 123 | 246 | 1 | — | 1,164 |
| Acquisition-related integration costs (2) | — | — | — | 139 | — | 139 |
| Adjusted operating income (loss) | $4,955 | $2,508 | $2,959 | $(628) | $(353) | $9,441 |
(1) The Company’s acquisition activities have resulted in the recognition of intangible assets as required under the acquisition method of accounting which consist primarily of trademarks, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired. Definite-lived intangible assets are amortized over their estimated useful lives and are tested for impairment when events indicate that the carrying value may not be recoverable. The amortization of intangible assets is reflected in the Company’s unaudited GAAP condensed consolidated statements of operations in operating expenses within each segment. Although intangible assets contribute to the Company’s revenue generation, the amortization of intangible assets does not directly relate to the underwriting of the Company’s insurance products, the services performed for the Company’s customers or the sale of the Company’s products or services. Additionally, intangible asset amortization expense typically fluctuates based on the size and timing of the Company’s acquisition activity. Accordingly, the Company believes excluding the amortization of intangible assets enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current performance and to analyze underlying business performance and trends. Intangible asset amortization excluded from the related non-GAAP financial measure represents the entire amount recorded within the Company’s GAAP financial statements, and the revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. Intangible asset amortization is excluded from the related non-GAAP financial measure because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised.
(2) During the three and six months ended June 30, 2021 and 2020, acquisition-related integration costs relate to the Company’s acquisition (the “Aetna Acquisition”) of Aetna Inc. (“Aetna”). The acquisition-related integration costs are reflected in the Company’s unaudited GAAP condensed consolidated statements of operations in operating expenses within the Corporate/Other segment.
(3) In June 2021, the Company received $61 million related to a purchase price working capital adjustment for an acquisition completed during the first quarter of 2020. The resolution of this matter occurred subsequent to the acquisition accounting measurement period and is reflected in the Company’s unaudited GAAP condensed consolidated statements of operations for the three and six months ended June 30, 2021 as a reduction of operating expenses within the Health Care Benefits segment.
Health Care Benefits Segment
The following table summarizes the Health Care Benefits segment’s performance for the respective periods:
| In millions, except percentages and basis points (“bps”) Revenues: | Three Months Ended June 30, 2021 | 2020 | Six Months Ended June 30, 2021 | 2020 | Change Three Months Ended June 30, 2021 vs 2020 $% | Six Months Ended June 30, 2021 vs 2020 $% | ||
|---|---|---|---|---|---|---|---|---|
| Premiums | $18,968 | $16,913 | $37,910 | $34,534 | $2,055 | 12.2% | $3,376 | 9.8% |
| Services | 1,420 | 1,428 | 2,813 | 2,912 | (8) | (0.6)% | (99) | (3.4)% |
| Net investment income | 137 | 127 | 285 | 220 | 10 | 7.9% | 65 | 29.5% |
| Total revenues | 20,525 | 18,468 | 41,008 | 37,666 | 2,057 | 11.1% | 3,342 | 8.9% |
| Benefit costs | 15,954 | 11,884 | 31,711 | 26,400 | 4,070 | 34.2% | 5,311 | 20.1% |
| MBR | 84.1% | 70.3% | 83.6% | 76.4% | 1,380 | bps | 720 | bps |
| Operating expenses | $3,298 | $3,518 | $6,644 | $7,105 | $(220) | (6.3)% | $(461) | (6.5)% |
| Operating expenses as a % of total revenues | 16.1% | 19.0% | 16.2% | 18.9% | ||||
| Operating income | $1,273 | $3,066 | $2,653 | $4,161 | $(1,793) | (58.5)% | $(1,508) | (36.2)% |
| Operating income as a % of total revenues | 6.2% | 16.6% | 6.5% | 11.0% | ||||
| Adjusted operating income (1) | $1,614 | $3,464 | $3,396 | $4,955 | $(1,850) | (53.4)% | $(1,559) | (31.5)% |
| Adjusted operating income as a % of total revenues | 7.9% | 18.8% | 8.3% | 13.2% | ||||
| Premium revenues (by business): | ||||||||
| Government | $13,897 | $11,976 | $27,814 | $24,445 | $1,921 | 16.0% | $3,369 | 13.8% |
| Commercial | 5,071 | 4,937 | 10,096 | 10,089 | 134 | 2.7% | 7 | 0.1% |
(1) See “Segment Analysis” above in this report for a reconciliation of Health Care Benefits segment operating income (GAAP measure) to adjusted operating income, which represents the Company’s principal measure of segment performance.
Commentary - Three Months Ended June 30, 2021 vs. 2020
Revenues
- Total revenues increased $2.1 billion, or 11.1%, to $20.5 billion in the three months ended June 30, 2021 compared to the prior year primarily driven by growth in the Government Services business, partially offset by the unfavorable impact of the repeal of the HIF for 2021.
Medical Benefit Ratio (“MBR”)
- Medical benefit ratio is calculated as benefit costs divided by premium revenues and represents the percentage of premium revenues spent on medical benefits for the Company’s Insured members. Management uses MBR to assess the underlying business performance and underwriting of its insurance products, understand variances between actual results and expected results and identify trends in period-over-period results. MBR provides management and investors with information useful in assessing the operating results of the Company’s Insured Health Care Benefits products.
- The MBR increased from 70.3% to 84.1% in the three months ended June 30, 2021 compared to the prior year primarily driven by the deferral of elective procedures and other discretionary utilization in response to the COVID-19 pandemic during the three months ended June 30, 2020 and the repeal of the HIF for 2021.
Operating expenses
- Operating expenses in the Health Care Benefits segment include selling, general and administrative expenses and depreciation and amortization expenses.
- Operating expenses decreased $220 million, or 6.3%, in the three months ended June 30, 2021 compared to the prior year. The decrease in operating expenses was primarily due to the repeal of the HIF for 2021, the impact of cost savings initiatives in the three months ended June 30, 2021 and the receipt of a $61 million purchase price working capital adjustment subsequent to the acquisition accounting measurement period related to an acquisition completed during the
first quarter of 2020, which was recorded as a reduction in operating expenses in the three months ended June 30, 2021. These decreases were partially offset by incremental operating expenses to support the growth in the Government Services business described above.
- Operating expenses as a percentage of total revenues decreased to 16.1% in the three months ended June 30, 2021 compared to 19.0% in the prior year. The decrease in operating expenses as a percentage of total revenues was primarily due to the repeal of the HIF for 2021.
Adjusted operating income
- Adjusted operating income decreased $1.9 billion, or 53.4% in the three months ended June 30, 2021 compared to the prior year. The decrease in adjusted operating income was primarily driven by the deferral of elective procedures and other discretionary utilization in response to the COVID-19 pandemic during the three months ended June 30, 2020.
Commentary - Six Months Ended June 30, 2021 vs. 2020
Revenues
- Total revenues increased $3.3 billion, or 8.9%, to $41.0 billion in the six months ended June 30, 2021 compared to the prior year primarily driven by growth in the Government Services business, partially offset by the unfavorable impact of the repeal of the HIF for 2021.
Medical Benefit Ratio (“MBR”)
- The MBR increased from 76.4% to 83.6% in the six months ended June 30, 2021 compared to the prior year primarily driven by the deferral of elective procedures and other discretionary utilization in response to the COVID-19 pandemic during the six months ended June 30, 2020 and the repeal of the HIF for 2021. These increases were partially offset by higher favorable development of prior-years’ health care cost estimates in the six months ended June 30, 2021 compared to the prior year.
Operating expenses
- Operating expenses decreased $461 million, or 6.5%, in the six months ended June 30, 2021 compared to the prior year. The decrease in operating expenses was primarily due to the repeal of the HIF for 2021 and the impact of cost savings initiatives in the six months ended June 30, 2021, partially offset by incremental operating expenses to support the growth in the Government Services business described above.
- Operating expenses as a percentage of total revenues decreased to 16.2% in the six months ended June 30, 2021 compared to 18.9% in the prior year. The decrease in operating expenses as a percentage of total revenues was primarily due to the repeal of the HIF for 2021.
Adjusted operating income
- Adjusted operating income decreased $1.6 billion, or 31.5% in the six months ended June 30, 2021 compared to the prior year. The decrease in adjusted operating income was primarily driven by the deferral of elective procedures and other discretionary utilization in response to the COVID-19 pandemic during the six months ended June 30, 2020, partially offset by improved performance in the Government Services business.
The following table summarizes the Health Care Benefits segment’s medical membership for the respective periods:
In thousands
| June 30, 2021 Insured ASC Medical membership: | Total | March 31, 2021 Insured | ASC | Total | December 31, 2020 Insured | ASC | Total | June 30, 2020 Insured | ASC | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Commercial 3,183 13,541 | 16,724 | 3,201 | 13,584 | 16,785 | 3,258 | 13,644 | 16,902 | 3,298 | 14,179 | 17,477 |
| Medicare Advantage 2,911 — | 2,911 | 2,874 | — | 2,874 | 2,705 | — | 2,705 | 2,651 | — | 2,651 |
| Medicare Supplement 1,193 — | 1,193 | 1,146 | — | 1,146 | 1,082 | — | 1,082 | 954 | — | 954 |
| Medicaid 2,231 451 | 2,682 | 2,184 | 637 | 2,821 | 2,100 | 623 | 2,723 | 1,918 | 586 | 2,504 |
| Total medical membership 9,518 13,992 | 23,510 | 9,405 | 14,221 | 23,626 | 9,145 | 14,267 | 23,412 | 8,821 | 14,765 | 23,586 |
| Supplemental membership information: | ||||||||||
| Medicare Prescription Drug Plan (standalone) | 5,704 | 5,694 | 5,490 | 5,575 |
Medical Membership
- Medical membership represents the number of members covered by the Company’s Insured and ASC medical products and related services at a specified point in time. Management uses this metric to understand variances between actual medical
membership and expected amounts as well as trends in period-over-period results. This metric provides management and investors with information useful in understanding the impact of medical membership on segment total revenues and operating results.
- Medical membership as of June 30, 2021 of 23.5 million decreased 116,000 members compared with March 31, 2021, primarily reflecting declines in Medicaid and Commercial products, partially offset by an increase in Medicare products. The decline in Medicaid membership reflects the loss of a large ASC customer during the three months ended June 30, 2021.
- Medical membership as of June 30, 2021 of 23.5 million decreased 76,000 members compared with June 30, 2020 primarily reflecting a decline in Commercial products, partially offset by increases in Medicare and Medicaid products.
Medicare Update
On January 15, 2021, the U.S. Centers for Medicare & Medicaid Services issued its final notice detailing final 2022 Medicare Advantage benchmark payment rates (the “Final Notice”). Final 2022 Medicare Advantage rates resulted in an increase in industry benchmark rates of approximately 4.1%.
Pharmacy Services Segment
The following table summarizes the Pharmacy Services segment’s performance for the respective periods:
In millions, except percentages
| Revenues: | Three Months Ended June 30, 2021 | 2020 | Six Months Ended June 30, 2021 | 2020 | Change Three Months Ended June 30, 2021 vs 2020 $% | Six Months Ended June 30, 2021 vs 2020 $% | ||
|---|---|---|---|---|---|---|---|---|
| Products | $38,010 | $34,595 | $74,077 | $69,341 | $3,415 | 9.9% | $4,736 | 6.8% |
| Services | 304 | 294 | 558 | 531 | 10 | 3.4% | 27 | 5.1% |
| Total revenues | 38,314 | 34,889 | 74,635 | 69,872 | 3,425 | 9.8% | 4,763 | 6.8% |
| Cost of products sold | 36,266 | 33,271 | 70,789 | 66,774 | 2,995 | 9.0% | 4,015 | 6.0% |
| Operating expenses | 343 | 347 | 689 | 713 | (4) | (1.2)% | (24) | (3.4)% |
| Operating expenses as a % of total revenues | 0.9% | 1.0% | 0.9% | 1.0% | ||||
| Operating income | $1,705 | $1,271 | $3,157 | $2,385 | $434 | 34.1% | $772 | 32.4% |
| Operating income as a % of total revenues | 4.5% | 3.6% | 4.2% | 3.4% | ||||
| Adjusted operating income (1) | $1,755 | $1,327 | $3,262 | $2,508 | $428 | 32.3% | $754 | 30.1% |
| Adjusted operating income as a % of total revenues | 4.6% | 3.8% | 4.4% | 3.6% | ||||
| Revenues (by distribution channel): | ||||||||
| Pharmacy network (2) | $22,918 | $20,536 | $44,811 | $41,636 | $2,382 | 11.6% | $3,175 | 7.6% |
| Mail choice (3) | 15,235 | 14,109 | 29,483 | 27,783 | 1,126 | 8.0% | 1,700 | 6.1% |
| Other | 161 | 244 | 341 | 453 | (83) | (34.0)% | (112) | (24.7)% |
| Pharmacy claims processed: (4) | ||||||||
| Total | 562.2 | 505.4 | 1,098.1 | 1,046.8 | 56.8 | 11.2% | 51.3 | 4.9% |
| Pharmacy network (2) | 479.3 | 425.1 | 934.7 | 886.2 | 54.2 | 12.7% | 48.5 | 5.5% |
| Mail choice (3) | 82.9 | 80.3 | 163.4 | 160.6 | 2.6 | 3.2% | 2.8 | 1.7% |
| Generic dispensing rate: (4) | ||||||||
| Total | 86.7% | 88.7% | 87.4% | 88.8% | ||||
| Pharmacy network (2) | 86.9% | 89.3% | 87.7% | 89.4% | ||||
| Mail choice (3) | 85.5% | 85.7% | 85.6% | 85.7% |
(1) See “Segment Analysis” above in this report for a reconciliation of Pharmacy Services segment operating income (GAAP measure) to adjusted operating income, which represents the Company’s principal measure of segment performance.
(2) Pharmacy network is defined as claims filled at retail and specialty retail pharmacies, including the Company’s retail pharmacies and LTC pharmacies, but excluding Maintenance Choice activity, which is included within the mail choice category. Maintenance Choice permits eligible client plan members to fill their maintenance prescriptions through mail order delivery or at a CVS Pharmacy retail store for the same price as mail order.
(3) Mail choice is defined as claims filled at a Pharmacy Services mail order facility, which includes specialty mail claims inclusive of Specialty Connect® claims picked up at a retail pharmacy, as well as prescriptions filled at the Company’s retail pharmacies under the Maintenance Choice program.
(4) Includes an adjustment to convert 90-day prescriptions to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription.
Commentary - Three Months Ended June 30, 2021 vs. 2020
Revenues
- Total revenues increased $3.4 billion, or 9.8%, to $38.3 billion in the three months ended June 30, 2021 compared to the prior year primarily driven by increased pharmacy claims volume, growth in specialty pharmacy and brand inflation, partially offset by continued price compression.
Operating expenses
- Operating expenses in the Pharmacy Services segment include selling, general and administrative expenses; depreciation and amortization expense; and expenses related to specialty retail pharmacies, which include store and administrative payroll, employee benefits and occupancy costs.
- Operating expenses as a percentage of total revenues remained relatively consistent at 0.9% and 1.0% in the three-month periods ended June 30, 2021 and 2020, respectively.
Adjusted operating income
- Adjusted operating income increased $428 million, or 32.3% in the three months ended June 30, 2021 compared to the prior year. The increase in adjusted operating income was primarily driven by improved purchasing economics that reflected products and services of our group purchasing organization that was launched in the second quarter of 2020 and specialty pharmacy (including pharmacy and/or administrative services for providers and Covered Entities), as well as increased pharmacy claims volume. These increases were partially offset by continued price compression.
- As you review the Pharmacy Services segment’s performance in this area, you should consider the following important information about the business:
- The Company’s efforts to (i) retain existing clients, (ii) obtain new business and (iii) maintain or improve the rebates, fees and/or discounts the Company receives from manufacturers, wholesalers and retail pharmacies continue to have an impact on adjusted operating income. In particular, competitive pressures in the PBM industry have caused the Company and other PBMs to continue to share with clients a larger portion of rebates, fees and/or discounts received from pharmaceutical manufacturers. In addition, marketplace dynamics and regulatory changes have limited the Company’s ability to offer plan sponsors pricing that includes retail network “differential” or “spread,” and the Company expects these trends to continue. The “differential” or “spread” is any difference between the drug price charged to plan sponsors, including Medicare Part D plan sponsors, by a PBM and the price paid for the drug by the PBM to the dispensing provider.
Pharmacy claims processed
- Total pharmacy claims processed represents the number of prescription claims processed through our pharmacy benefits manager and dispensed by either our retail network pharmacies or our own mail and specialty pharmacies. Management uses this metric to understand variances between actual claims processed and expected amounts as well as trends in period-over-period results. This metric provides management and investors with information useful in understanding the impact of pharmacy claim volume on segment total revenues and operating results.
- The Company’s pharmacy network claims processed on a 30-day equivalent basis increased 12.7% to 479.3 million claims in the three months ended June 30, 2021 compared to 425.1 million claims in the prior year primarily driven by net new business, COVID-19 vaccinations and increased new therapy prescriptions, which were adversely impacted by the COVID-19 pandemic during the three months ended June 30, 2020.
- The Company’s mail choice claims processed on a 30-day equivalent basis increased 3.2% to 82.9 million claims in the three months ended June 30, 2021 compared to 80.3 million claims in the prior year primarily driven by net new business and the continued adoption of Maintenance Choice offerings.
- Excluding the impact of COVID-19 vaccinations, total pharmacy claims processed increased 8.4% on a 30-day equivalent basis for the three months ended June 30, 2021 compared to the prior year.
Generic dispensing rate
- Generic dispensing rate is calculated by dividing the Pharmacy Services segment’s generic drug prescriptions processed or filled by its total prescriptions processed or filled. Management uses this metric to evaluate the effectiveness of the business at encouraging the use of generic drugs when they are available and clinically appropriate, which aids in decreasing costs for client members and retail customers. This metric provides management and investors with information useful in understanding trends in segment total revenues and operating results.
- The Pharmacy Services segment’s total generic dispensing rate decreased to 86.7% in the three months ended June 30, 2021 compared to 88.7% in the prior year. The decrease in the segment’s generic dispensing rate was primarily driven by an increase in brand prescriptions, largely attributable to COVID-19 vaccinations in the three months ended June 30, 2021. Excluding the impact of COVID-19 vaccinations, the segment’s total generic dispensing rate increased to 89.0% in the three months ended June 30, 2021.
Commentary - Six Months Ended June 30, 2021 vs. 2020
Revenues
- Total revenues increased $4.8 billion, or 6.8%, to $74.6 billion in the six months ended June 30, 2021 compared to the prior year primarily driven by increased pharmacy claims volume, growth in specialty pharmacy and brand inflation, partially offset by continued price compression.
Operating expenses
- Operating expenses as a percentage of total revenues remained relatively consistent at 0.9% and 1.0% in the six-month periods ended June 30, 2021 and 2020, respectively.
Adjusted operating income
- Adjusted operating income increased $754 million, or 30.1% in the six months ended June 30, 2021 compared to the prior year. The increase in adjusted operating income was primarily driven by improved purchasing economics that reflected products and services of our group purchasing organization that was launched in the second quarter of 2020 and specialty pharmacy (including pharmacy and/or administrative services for providers and Covered Entities), partially offset by continued price compression.
Pharmacy claims processed
- The Company’s pharmacy network claims processed on a 30-day equivalent basis increased 5.5% to 934.7 million claims in the six months ended June 30, 2021 compared to 886.2 million claims in the prior year primarily driven by net new business and COVID-19 vaccinations.
- The Company’s mail choice claims processed on a 30-day equivalent basis increased 1.7% to 163.4 million claims in the six months ended June 30, 2021 compared to 160.6 million claims in the prior year primarily driven by net new business and the continued adoption of Maintenance Choice offerings.
- Excluding the impact of COVID-19 vaccinations, total pharmacy claims processed increased 3.0% on a 30-day equivalent basis for the six months ended June 30, 2021 compared to the prior year.
Generic dispensing rate
- The Pharmacy Services segment’s total generic dispensing rate decreased to 87.4% in the six months ended June 30, 2021 compared to 88.8% in the prior year. The decrease in the segment’s generic dispensing rate was primarily driven by an increase in brand prescriptions, largely attributable to COVID-19 vaccinations in the six months ended June 30, 2021. Excluding the impact of COVID-19 vaccinations, the segment’s total generic dispensing rate increased to 89.0% in the six months ended June 30, 2021.
Retail/LTC Segment
The following table summarizes the Retail/LTC segment’s performance for the respective periods:
In millions, except percentages
| Revenues: | Three Months Ended June 30, 2021 | 2020 | Six Months Ended June 30, 2021 | 2020 | Change Three Months Ended June 30, 2021 vs 2020 $% | Six Months Ended June 30, 2021 vs 2020 $% | ||
|---|---|---|---|---|---|---|---|---|
| Products | $23,609 | $21,476 | $46,003 | $43,998 | $2,133 | 9.9% | $2,005 | 4.6% |
| Services | 1,119 | 186 | 1,953 | 413 | 933 | 501.6% | 1,540 | 372.9% |
| Net investment income | — | — | 46 | — | — | —% | 46 | 100.0% |
| Total revenues | 24,728 | 21,662 | 48,002 | 44,411 | 3,066 | 14.2% | 3,591 | 8.1% |
| Cost of products sold | 17,952 | 16,220 | 34,994 | 32,798 | 1,732 | 10.7% | 2,196 | 6.7% |
| Operating expenses | 4,857 | 4,509 | 9,824 | 8,900 | 348 | 7.7% | 924 | 10.4% |
| Operating expenses as a % of total revenues | 19.6% | 20.8% | 20.5% | 20.0% | ||||
| Operating income | $1,919 | $933 | $3,184 | $2,713 | $986 | 105.7% | $471 | 17.4% |
| Operating income as a % of total revenues | 7.8% | 4.3% | 6.6% | 6.1% | ||||
| Adjusted operating income (1) | $2,049 | $1,057 | $3,443 | $2,959 | $992 | 93.9% | $484 | 16.4% |
| Adjusted operating income as a % of total revenues | 8.3% | 4.9% | 7.2% | 6.7% | ||||
| Revenues (by major goods/service lines): | ||||||||
| Pharmacy | $18,873 | $16,870 | $36,758 | $34,225 | $2,003 | 11.9% | $2,533 | 7.4% |
| Front Store | 5,254 | 4,653 | 9,896 | 9,861 | 601 | 12.9% | 35 | 0.4% |
| Other | 601 | 139 | 1,302 | 325 | 462 | 332.4% | 977 | 300.6% |
| Net investment income | — | — | 46 | — | — | —% | 46 | 100.0% |
| Prescriptions filled (2) | 394.4 | 345.4 | 769.8 | 720.5 | 49.0 | 14.2% | 49.3 | 6.8% |
| Same store sales increase (decrease): (3) | ||||||||
| Total | 12.3% | 2.4% | 6.2% | 5.7% | ||||
| Pharmacy | 12.4% | 4.6% | 8.2% | 6.9% | ||||
| Front Store | 12.0% | (4.5)% | (0.4)% | 1.7% | ||||
| Prescription volume (2) | 14.8% | 0.6% | 7.6% | 5.2% | ||||
| Generic dispensing rate (2) | 85.7% | 89.1% | 86.5% | 89.2% |
(1) See “Segment Analysis” above in this report for a reconciliation of Retail/LTC segment operating income (GAAP measure) to adjusted operating income, which represents the Company’s principal measure of segment performance.
(2) Includes an adjustment to convert 90-day prescriptions to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription.
(3) Same store sales and prescription volume represent the change in revenues and prescriptions filled in the Company’s retail pharmacy stores that have been operating for greater than one year, expressed as a percentage that indicates the increase or decrease relative to the comparable prior period. Same store metrics exclude revenues from MinuteClinic, revenues and prescriptions from LTC operations. Management uses these metrics to evaluate the performance of existing stores on a comparable basis and to inform future decisions regarding existing stores and new locations. Same-store metrics provide management and investors with information useful in understanding the portion of current revenues and prescriptions resulting from organic growth in existing locations versus the portion resulting from opening new stores.
Commentary - Three Months Ended June 30, 2021 vs. 2020
Revenues
- Total revenues increased $3.1 billion, or 14.2%, to $24.7 billion in the three months ended June 30, 2021 compared to the prior year primarily driven by increased prescription volume, COVID-19 vaccinations and diagnostic testing and higher front store revenues. These increases were partially offset by continued pharmacy reimbursement pressure. COVID-19 vaccinations and diagnostic testing contributed nearly a third of the increase in the segment’s revenues for the three months
ended June 30, 2021 compared to the prior year, as the prior year included an immaterial impact from diagnostic testing and no COVID-19 vaccinations.
- Pharmacy same store sales increased 12.4% in the three months ended June 30, 2021 compared to the prior year. The increase was primarily driven by the 14.8% increase in pharmacy same store prescription volume on a 30-day equivalent basis and brand inflation. These increases were partially offset by continued pharmacy reimbursement pressure and the impact of recent generic introductions.
- Front store same store sales increased 12.0% in the three months ended June 30, 2021 compared to the prior year. The increase was primarily due to reduced customer traffic in the segment’s retail pharmacies due to shelter-in-place orders in response to the COVID-19 pandemic in the three months ended June 30, 2020 as well as strength across all product categories in the three months ended June 30, 2021.
- Other revenues increased $462 million in the three months ended June 30, 2021 compared to the prior year. The increase was primarily due to increased COVID-19 diagnostic testing in the three months ended June 30, 2021.
Operating expenses
- Operating expenses in the Retail/LTC segment include store payroll, store employee benefits, store occupancy costs, selling expenses, advertising expenses, depreciation and amortization expense and certain administrative expenses.
- Operating expenses increased $348 million, or 7.7%, in the three months ended June 30, 2021 compared to the prior year. The increase was primarily due to incremental costs associated with increased volume including COVID-19 vaccinations and diagnostic testing, partially offset by a $125 million gain from an anti-trust legal settlement recorded in the three months ended June 30, 2021 and the absence of incremental expenses associated with the Company’s initial COVID-19 pandemic mitigation efforts incurred in the three months ended June 30, 2020.
- Operating expenses as a percentage of total revenues decreased to 19.6% in the three months ended June 30, 2021 compared to 20.8% in the prior year. The decrease in operating expenses as a percentage of total revenues was primarily driven by the increases in total revenues described above.
Adjusted operating income
- Adjusted operating income increased $992 million, or 93.9% in the three months ended June 30, 2021 compared to the prior year. The increase in adjusted operating income was primarily driven by the increased prescription and front store volume described above, COVID-19 vaccinations and diagnostic testing and a $125 million gain from an anti-trust legal settlement recorded in the three months ended June 30, 2021. These increases were partially offset by continued pharmacy reimbursement pressure.
- As you review the Retail/LTC segment’s performance in this area, you should consider the following important information about the business:
- The segment’s adjusted operating income has been adversely affected by the efforts of managed care organizations, PBMs and governmental and other third-party payors to reduce their prescription drug costs, including the use of restrictive networks, as well as changes in the mix of business within the pharmacy portion of the Retail/LTC segment. If the pharmacy reimbursement pressure accelerates, the segment may not be able grow revenues, and its adjusted operating income could be adversely affected.
- The increased use of generic drugs has positively impacted the segment’s adjusted operating income but has resulted in third-party payors augmenting their efforts to reduce reimbursement payments to retail pharmacies for prescriptions. This trend, which the Company expects to continue, reduces the benefit the segment realizes from brand to generic drug conversions.
- The segment’s adjusted operating income benefited from the administration of COVID-19 vaccinations and diagnostic testing, which contributed approximately half of the increase in adjusted operating income for the three months ended June 30, 2021 compared to the prior year.
Prescriptions filled
- Prescriptions filled represents the number of prescriptions dispensed through the Retail/LTC segment’s pharmacies. Management uses this metric to understand variances between actual prescriptions dispensed and expected amounts as well as trends in period-over-period results. This metric provides management and investors with information useful in understanding the impact of prescription volume on segment total revenues and operating results.
- Prescriptions filled increased 14.2% on a 30-day equivalent basis in the three months ended June 30, 2021 compared to the prior year primarily driven by COVID-19 vaccinations, as well as the continued adoption of patient care programs and increased new therapy prescriptions, both of which were adversely impacted by the COVID-19 pandemic during the three months ended June 30, 2020. Excluding the impact of COVID-19 vaccinations, prescriptions filled increased 9.3% on a 30-day equivalent basis for the three months ended June 30, 2021 compared to the prior year.
Generic dispensing rate
- Generic dispensing rate is calculated by dividing the Retail/LTC segment’s generic drug prescriptions filled by its total prescriptions filled. Management uses this metric to evaluate the effectiveness of the business at encouraging the use of generic drugs when they are available and clinically appropriate, which aids in decreasing costs for client members and retail customers. This metric provides management and investors with information useful in understanding trends in segment total revenues and operating results.
- The Retail/LTC segment’s generic dispensing rate decreased to 85.7% in the three months ended June 30, 2021 compared to 89.1% in the prior year. The decrease in the segment’s generic dispensing rate was primarily driven by an increase in brand prescriptions, largely attributable to COVID-19 vaccinations in the three months ended June 30, 2021. Excluding the impact of COVID-19 vaccinations, the segment’s total generic dispensing rate increased to 89.5% in the three months ended June 30, 2021.
Commentary - Six Months Ended June 30, 2021 vs. 2020
Revenues
- Total revenues increased $3.6 billion, or 8.1%, to $48.0 billion in the six months ended June 30, 2021 compared to the prior year primarily driven by COVID-19 vaccinations and diagnostic testing, increased prescription volume and brand inflation. These increases were partially offset by continued pharmacy reimbursement pressure and the impact of recent generic introductions. COVID-19 vaccinations and diagnostic testing contributed nearly half of the increase in the segment’s revenues for the six months ended June 30, 2021, as the prior year included an immaterial impact from diagnostic testing and no COVID-19 vaccinations.
- Pharmacy same store sales increased 8.2% in the six months ended June 30, 2021 compared to the prior year. The increase was primarily driven by the 7.6% increase in pharmacy same store prescription volume on a 30-day equivalent basis and brand inflation. These increases were partially offset by continued pharmacy reimbursement pressure and the impact of recent generic introductions.
- Front store same store sales decreased 0.4% in the six months ended June 30, 2021 compared to the prior year. The decrease was primarily due to a weak cough, cold and flu season in the first quarter of 2021, partially offset by increased consumer health and beauty care sales in the six months ended June 30, 2021.
- Other revenues increased $977 million in the six months ended June 30, 2021 compared to the prior year. The increase was primarily due to increased COVID-19 diagnostic testing in the six months ended June 30, 2021.
Operating expenses
- Operating expenses increased $924 million, or 10.4%, in the six months ended June 30, 2021 compared to the prior year. The increase was primarily due to incremental costs associated with increased volume including COVID-19 vaccinations and diagnostic testing, partially offset by the absence of incremental expenses associated with the Company’s initial COVID-19 pandemic mitigation efforts incurred in the six months ended June 30, 2020.
- Operating expenses as a percentage of total revenues increased to 20.5% in the six months ended June 30, 2021 compared to 20.0% in the prior year. The increase in operating expenses as a percentage of total revenues was primarily driven by the increases in operating expenses described above.
Adjusted operating income
- Adjusted operating income increased $484 million, or 16.4% in the six months ended June 30, 2021 compared to the prior year. The increase in adjusted operating income was primarily driven by COVID-19 vaccinations and diagnostic testing, increased prescription volume and improved generic drug purchasing. These increases were partially offset by continued pharmacy reimbursement pressure. COVID-19 vaccinations and diagnostic testing contributed approximately 20% of the segment’s adjusted operating income for the six months ended June 30, 2021.
Prescriptions filled
- Prescriptions filled increased 6.8% on a 30-day equivalent basis in the six months ended June 30, 2021 compared to the prior year primarily driven by COVID-19 vaccinations and the continued adoption of patient care programs. Excluding the impact of COVID-19 vaccinations, prescriptions filled increased 3.2% on a 30-day equivalent basis for the six months ended June 30, 2021 compared to the prior year.
Generic dispensing rate
- The Retail/LTC segment’s generic dispensing rate decreased to 86.5% in the six months ended June 30, 2021 compared to 89.2% in the prior year. The decrease in the segment’s generic dispensing rate was primarily driven by an increase in brand prescriptions, largely attributable to COVID-19 vaccinations in the six months ended June 30, 2021. Excluding the impact of COVID-19 vaccinations, the segment’s total generic dispensing rate increased to 89.6% in the six months ended June 30, 2021.
Corporate/Other Segment
The following table summarizes the Corporate/Other segment’s performance for the respective periods:
In millions, except percentages
| Revenues: | Three Months Ended June 30, 2021 | 2020 | Six Months Ended June 30, 2021 | 2020 | Change Three Months Ended June 30, 2021 vs 2020 $% | Six Months Ended June 30, 2021 vs 2020 $% | ||
|---|---|---|---|---|---|---|---|---|
| Premiums | $15 | $14 | $33 | $33 | $1 | 7.1% | $— | —% |
| Services | 15 | 15 | 29 | 17 | — | —% | 12 | 70.6% |
| Net investment income | 152 | 57 | 255 | 126 | 95 | 166.7% | 129 | 102.4% |
| Total revenues | 182 | 86 | 317 | 176 | 96 | 111.6% | 141 | 80.1% |
| Cost of products sold | 8 | — | 16 | — | 8 | 100.0% | 16 | 100.0% |
| Benefit costs | 54 | 51 | 99 | 119 | 3 | 5.9% | (20) | (16.8)% |
| Operating expenses | 529 | 448 | 956 | 825 | 81 | 18.1% | 131 | 15.9% |
| Operating loss | (409) | (413) | (754) | (768) | 4 | 1.0% | 14 | 1.8% |
| Adjusted operating loss (1) | (369) | (343) | (672) | (628) | (26) | (7.6)% | (44) | (7.0)% |
(1) See “Segment Analysis” above in this report for a reconciliation of Corporate/Other segment operating loss (GAAP measure) to adjusted operating loss, which represents the Company’s principal measure of segment performance.
Commentary - Three Months Ended June 30, 2021 vs. 2020
Revenues
- Revenues primarily relate to products for which the Company no longer solicits or accepts new customers, such as large case pensions and long-term care insurance products.
- Total revenues increased $96 million, or 111.6% to $182 million in the three months ended June 30, 2021 compared to the prior year primarily driven by higher net investment income, primarily related to private equity investments.
Adjusted operating loss
- Adjusted operating loss increased $26 million in the three months ended June 30, 2021 compared to the prior year. The increase was primarily driven by higher employee benefit costs and incremental operating expenses associated with Company’s investments in transformation, partially offset by the increase in net investment income in the three months ended June 30, 2021 described above.
Commentary - Six Months Ended June 30, 2021 vs. 2020
Revenues
- Total revenues increased $141 million, or 80.1% to $317 million in the six months ended June 30, 2021 compared to the prior year primarily driven by higher net investment income, primarily related to private equity investments.
Adjusted operating loss
- Adjusted operating loss increased $44 million in the six months ended June 30, 2021 compared to the prior year. The increase was primarily driven by higher employee benefit costs and incremental operating expenses associated with Company’s investments in transformation, partially offset by the increase in net investment income in the six months ended June 30, 2021 described above.
Liquidity and Capital Resources
Cash Flows
The Company maintains a level of liquidity sufficient to allow it to meet its cash needs in the short-term. Over the long term, the Company manages its cash and capital structure to maximize shareholder return, maintain its financial condition and maintain flexibility for future strategic initiatives. The Company continuously assesses its regulatory capital requirements, working capital needs, debt and leverage levels, debt maturity schedule, capital expenditure requirements, dividend payouts, potential share repurchases and future investments or acquisitions. The Company believes its operating cash flows, commercial paper program, credit facilities, sale-leaseback program, as well as any potential future borrowings, will be sufficient to fund these future payments and long-term initiatives. As of June 30, 2021, the Company had approximately $7.1 billion in cash and cash equivalents, $1.9 billion of which was held by the parent company or nonrestricted subsidiaries.
The net change in cash, cash equivalents and restricted cash during the six months ended June 30, 2021 and 2020 was as follows:
In millions, except percentages
| Six Months Ended June 30, 2021 | 2020 | Change $% | ||
|---|---|---|---|---|
| Net cash provided by operating activities | $8,739 | $10,424 | $(1,685) | (16.2)% |
| Net cash used in investing activities | (2,974) | (2,930) | (44) | 1.5% |
| Net cash provided by (used in) financing activities | (6,558) | 1,697 | (8,255) | (486.4)% |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $(793) | $9,191 | $(9,984) | (108.6)% |
Commentary
- Net cash provided by operating activities decreased by $1.7 billion in the six months ended June 30, 2021 compared to the prior year. The decrease was primarily due to items that favorably impacted operating cash flows in the six months ended June 30, 2020 that did not recur during the current year including: the deferral of quarterly estimated federal and state income tax payments normally due during the second quarter of 2020 until the third quarter of 2020, reduced benefit costs during the second quarter of 2020 due to the deferral of elective procedures and other discretionary utilization in the Health Care Benefits segment as a result of the COVID-19 pandemic and the timing of payments and pricing actions during 2020 designed to recover the HIF, which was paid in the third quarter of 2020.
- Net cash used in investing activities increased by $44 million in the six months ended June 30, 2021 compared to the prior year primarily due to increased net purchases of investments and property and equipment, largely offset by a decrease in cash used for acquisitions.
- Net cash used in financing activities was $6.6 billion in the six months ended June 30, 2021 compared to net cash provided by financing activities of $1.7 billion in the prior year. The decrease in cash provided by financing activities primarily related to increased repayments of long-term debt in the six months ended June 30, 2021 compared to the prior year and the absence of proceeds from the issuance of $4.0 billion of senior notes in the six months ended June 30, 2020.
Short-term Borrowings
Commercial Paper and Back-up Credit Facilities
The Company did not have any commercial paper outstanding as of June 30, 2021. In connection with its commercial paper program, the Company maintains a $2.0 billion, five-year unsecured back-up revolving credit facility, which expires on May 17, 2023, a $2.0 billion, five-year unsecured back-up revolving credit facility, which expires on May 16, 2024, and a $2.0 billion, five-year unsecured back-up revolving credit facility, which expires on May 11, 2026. The credit facilities allow for borrowings at various rates that are dependent, in part, on the Company’s public debt ratings and require the Company to pay a weighted average quarterly facility fee of approximately 0.03%, regardless of usage. As of June 30, 2021, there were no borrowings outstanding under any of the Company’s back-up credit facilities.
Federal Home Loan Bank of Boston
A subsidiary of the Company is a member of the Federal Home Loan Bank of Boston (the “FHLBB”). As a member, the subsidiary has the ability to obtain cash advances, subject to certain minimum collateral requirements. The maximum borrowing capacity available from the FHLBB as of June 30, 2021 was approximately $985 million. As of June 30, 2021, there were no outstanding advances from the FHLBB.
Debt Covenants
The Company’s back-up revolving credit facilities and unsecured senior notes contain customary restrictive financial and operating covenants. These covenants do not include an acceleration of the Company’s debt maturities in the event of a downgrade in the Company’s credit ratings. The Company does not believe the restrictions contained in these covenants materially affect its financial or operating flexibility. As of June 30, 2021, the Company was in compliance with all of its debt covenants.
Debt Ratings
As of June 30, 2021, the Company’s long-term debt was rated “Baa2” by Moody’s Investor Service, Inc. (“Moody’s”) and “BBB” by Standard & Poor’s Financial Services LLC (“S&P”), and its commercial paper program was rated “P-2” by Moody’s and “A-2” by S&P. The outlook on the Company’s long-term debt is “Stable” by Moody’s. In June 2021, S&P changed the outlook on the Company’s long-term debt from “Stable” to “Positive.” In assessing the Company’s credit strength, the Company believes that both Moody’s and S&P considered, among other things, the Company’s capital structure and financial policies as well as its consolidated balance sheet, its historical acquisition activity and other financial information. Although the Company currently believes its long-term debt ratings will remain investment grade, it cannot guarantee the future actions of Moody’s and/or S&P. The Company’s debt ratings have a direct impact on its future borrowing costs, access to capital markets and new store operating lease costs.
Share Repurchase Program
During the six months ended June 30, 2021 and 2020, the Company did not repurchase any shares of common stock. See Note 5 ‘‘Shareholders’ Equity’’ to the unaudited condensed consolidated financial statements for additional information on the Company’s share repurchase program.
Critical Accounting Policies
The Company prepares the unaudited condensed consolidated financial statements in conformity with generally accepted accounting principles, which require management to make certain estimates and apply judgment. Estimates and judgments are based on historical experience, current trends and other factors that management believes to be important at the time the unaudited condensed consolidated financial statements are prepared. On a regular basis, the Company reviews its accounting policies and how they are applied and disclosed in the unaudited condensed consolidated financial statements. While the Company believes the historical experience, current trends and other factors considered by management support the preparation of the unaudited condensed consolidated financial statements in conformity with generally accepted accounting principles, actual results could differ from estimates, and such differences could be material.
Recoverability of Goodwill
During 2020, the Company performed its required annual impairment test of goodwill. The results of this impairment test indicated that there was no impairment of goodwill as of the testing date. The goodwill impairment test resulted in the fair values of all of the Company’s reporting units exceeding their carrying values by significant margins, with the exception of the Commercial Business and LTC reporting units, which exceeded their carrying values by approximately 6% and 12%, respectively.
The fair value of the reporting units is estimated using a combination of a discounted cash flow method and a market multiple method. The determination of the fair value of the reporting units requires the Company to make significant assumptions and estimates. These assumptions and estimates primarily include the selection of appropriate peer group companies; control premiums and valuation multiples appropriate for acquisitions in the industries in which the Company competes; discount rates; terminal growth rates; and forecasts of revenue, operating income, depreciation and amortization, income taxes, capital expenditures and future working capital requirements. When determining these assumptions and preparing these estimates, the Company considers each reporting unit’s historical results and current operating trends; consolidated revenues, profitability and cash flow results and forecasts; and industry trends. The Company’s estimates can be affected by a number of factors, including general economic and regulatory conditions; the risk-free interest rate environment; the Company’s market capitalization; efforts of customers and payers to reduce costs, including their prescription drug costs, and/or increase member co-payments;
the continued efforts of competitors to gain market share, consumer spending patterns and the Company’s ability to achieve its revenue growth projections and execute on its cost reduction initiatives.
The LTC reporting unit has continued to face challenges that affect the Company’s ability to grow the LTC reporting unit’s business at the rate estimated when its 2020 goodwill impairment test was performed and may continue to do so. These challenges include lower net bed additions and the prolonged adverse impact of the COVID-19 pandemic, which resulted in more significant declines in occupancy rates experienced by the Company’s long-term care facility customers than previously anticipated. Some of the key assumptions included in the Company’s financial projections to determine the estimated fair value of the LTC reporting unit include client retention rates; occupancy rates in skilled nursing facilities; the financial health of skilled nursing facility customers; facility reimbursement pressures; the Company’s ability to extract cost savings from labor productivity and other initiatives; the geographies impacted and the severity and duration of COVID-19; COVID-19’s impact on health care utilization patterns; and the timing, scope and impact of stimulus legislation as well as other federal, state and local governmental responses to COVID-19. The fair value of the LTC reporting unit also is dependent on market multiples of peer group companies and the risk-free interest rate environment, which impacts the discount rate used in the discounted cash flow valuation method.
The COVID-19 pandemic continues to evolve. The impact COVID-19 will have on our businesses, operating results, cash flows and/or financial condition is uncertain, but the impact could be adverse and material. If the LTC reporting unit does not achieve its forecasts, it is reasonably possible in the near term that the goodwill of the LTC reporting unit could be deemed to be impaired by a material amount. As of June 30, 2021, the goodwill balance in the LTC reporting unit was $431 million.
For a full description of the Company’s other critical accounting policies, see “Critical Accounting Policies” in Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of the 2020 Form 10-K.
Cautionary Statement Concerning Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 (the “Reform Act”) provides a “safe harbor” for forward-looking statements, so long as (1) those statements are identified as forward-looking and (2) the statements are accompanied by meaningful cautionary statements that identify important factors that could cause actual results to differ materially from those discussed in the statement. We want to take advantage of these safe harbor provisions.
Certain information contained in this Quarterly Report on Form 10-Q (this “report”) is forward-looking within the meaning of the Reform Act or SEC rules. This information includes, but is not limited to the forward-looking information in Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) included in Part I, Item 2 of this report. In addition, throughout this report and our other reports and communications, we use the following words or variations or negatives of these words and similar expressions when we intend to identify forward-looking statements:
| · | Anticipates | · | Believes | · | Can | · | Continue | · | Could |
| · | Estimates | · | Evaluate | · | Expects | · | Explore | · | Forecast |
| · | Guidance | · | Intends | · | Likely | · | May | · | Might |
| · | Outlook | · | Plans | · | Potential | · | Predict | · | Probable |
| · | Projects | · | Seeks | · | Should | · | View | · | Will |
All statements addressing the future operating performance of CVS Health or any segment or any subsidiary and/or future events or developments, including statements relating to the projected impact of COVID-19 on the Company’s businesses, investment portfolio, operating results, cash flows and/or financial condition, statements relating to corporate strategy, statements relating to future revenue, operating income or adjusted operating income, earnings per share or adjusted earnings per share, Health Care Benefits segment business, sales results and/or trends, medical cost trends, medical membership, Medicare Part D membership, medical benefit ratios and/or operations, Pharmacy Services segment business, sales results and/or trends and/or operations, Retail/LTC segment business, sales results and/or trends and/or operations, incremental investment spending, interest expense, effective tax rate, weighted-average share count, cash flow from operations, net capital expenditures, cash available for debt repayment, integration synergies, net synergies, integration costs, enterprise modernization, transformation, leverage ratio, cash available for enhancing shareholder value, inventory reduction, turn rate and/or loss rate, debt ratings, the Company’s ability to attract or retain customers and clients, store development and/or relocations, new product development, and the impact of industry and regulatory developments as well as statements expressing optimism or pessimism about future operating results or events, are forward-looking statements within the meaning of the Reform Act.
Forward-looking statements rely on a number of estimates, assumptions and projections concerning future events, and are subject to a number of significant risks and uncertainties and other factors that could cause actual results to differ materially from those statements. Many of these risks and uncertainties and other factors are outside our control. Certain of these risks and uncertainties and other factors are described under “Risk Factors” included in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020; these are not the only risks and uncertainties we face. There can be no assurance that the Company has identified all the risks that affect it. Additional risks and uncertainties not presently known to the Company or that the Company currently believes to be immaterial also may adversely affect the Company’s businesses. If any of those risks or uncertainties develops into actual events, those events or circumstances could have a material adverse effect on the Company’s businesses, operating results, cash flows, financial condition and/or stock price, among other effects.
You should not put undue reliance on forward-looking statements. Any forward-looking statement speaks only as of the date of this report, and we disclaim any intention or obligation to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise.
Market risk
As filed, 364 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company has not experienced any material changes in exposures to market risk since December 31, 2020. See the information contained in Part II, Item 7A “Quantitative and Qualitative Disclosures About Market Risk” of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 for a discussion of the Company’s exposures to market risk.
Controls and procedures
As filed, 1,042 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of disclosure controls and procedures: The Company’s Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Securities Exchange Act Rules 13a‑15(f) and 15d‑15(f)) as of June 30, 2021, have concluded that as of such date the Company’s disclosure controls and procedures were adequate and effective and designed to provide reasonable assurance that material information relating to the Company and its subsidiaries would be made known to such officers on a timely basis.
Changes in internal control over financial reporting: There has been no change in the Company’s internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or Rule 15d-15 that occurred in the three months ended June 30, 2021 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
Risk factors
As filed, 360 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There have been no material changes to the “Risk Factors” disclosed in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020. Those risk factors could adversely affect the Company’s businesses, operating results, cash flows and/or financial condition as well as the market price of the Company’s common shares.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-04-01 to 2021-06-30 | $72.62bn | us-gaap:Revenues |
| Revenue | 6 months2021-01-01 to 2021-06-30 | $141.71bn | us-gaap:Revenues |
| Cost of revenue | 3 months2021-04-01 to 2021-06-30 | $43.52bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2021-01-01 to 2021-06-30 | $84.41bn | us-gaap:CostOfGoodsAndServicesSold |
| Operating income | 3 months2021-04-01 to 2021-06-30 | $4.33bn | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2021-01-01 to 2021-06-30 | $7.90bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2021-04-01 to 2021-06-30 | $636.0m | us-gaap:InterestExpense |
| Interest expense | 6 months2021-01-01 to 2021-06-30 | $1.29bn | us-gaap:InterestExpense |
| Income tax | 3 months2021-04-01 to 2021-06-30 | $944.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2021-01-01 to 2021-06-30 | $1.69bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2021-04-01 to 2021-06-30 | $2.78bn | us-gaap:NetIncomeLoss |
| Net income | 6 months2021-01-01 to 2021-06-30 | $5.01bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-04-01 to 2021-06-30 | $2.10 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2021-01-01 to 2021-06-30 | $3.78 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2021-04-01 to 2021-06-30 | $2.11 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2021-01-01 to 2021-06-30 | $3.80 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2021-04-01 to 2021-06-30 | 1,327,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2021-01-01 to 2021-06-30 | 1,325,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2021-01-01 to 2021-06-30 | $8.74bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2021-01-01 to 2021-06-30 | $1.31bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months2021-01-01 to 2021-06-30 | $1.31bn | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2021-06-30 | $7.12bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-06-30 | $56.56bn | us-gaap:AssetsCurrent |
| Total assets | At period end2021-06-30 | $231.16bn | us-gaap:Assets |
| Current liabilities | At period end2021-06-30 | $59.31bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-06-30 | $157.60bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-06-30 | $73.24bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000064803-21-000028. Last ingested by Listed: Nov 6, 2026, 17:47 ET. Listed shows no prices and gives no investment advice.